Ermium Therapeutics strengthens its management team with the appointment of Stéphane Durant des Aulnois as CFO

Ermium management team is growing with the appointment of Stéphane Durant des Aulnois as CFO. Stéphane is bringing a wide experience in terms of positions in finance and investor relationship, and more recently in business development. 

Prior to joining Ermium Therapeutics, Stéphane Durant des Aulnois served as Chief Financial Officer & Head of Alliances and Business development at Lysogene, a phase 3 gene therapy company listed on Euronext, where he successfully led capital raising activities and closed the acquisition of two assets. Previously, Stéphane spent nine years at Ipsen, first as Vice-President Head of Investor Relations for the Group, then as CFO of Ipsen Iberia, in charge of financial, procurement and supply chain activities. Earlier in his career, he worked in Private Equity at LaSalle Investment management, at Calyon Americas and at Exane BNP Paribas as a sell-side research Analyst. He holds a master’s degree (MSc) in Accounting and Finance from the London School of Economics (LSE) and in Management from Paris Dauphine University. He also holds an Executive Leadership degree from Harvard Business School.